Welcome to the 15th installment of the Main Street Value Investor (MSVI) series, the happy people edition, exclusively on Seeking Alpha (Subscribers to MSVI Member Forum got the first look at this research).

As a holding company, Johnson & Johnson (NYSE:JNJ) manages a portfolio of globally recognized - and perhaps universally expensive - health and beauty products, medical devices, and over-the-counter and prescription drugs. As a stock, JNJ appears neither grossly underpriced nor overpriced.

The company’s legacy of sound fundamentals and dividend aristocracy presents an enduring opportunity as a core portfolio, multi-year holding.

READ FULL ARTICLE HERE